2409479-24-7

Uses

IDO/Tubulin-IN-2 (HT2) is a potent TDO and tubulin inhibitor. IDO/Tubulin-IN-2 also shows potent activity against U87, HepG2, A549, HCT-116, and LO2 cancer cell lines, with IC50 values of 0.43, 0.036, 0.041, 0.095 and 1.04 μM, respectively. IDO/Tubulin-IN-2 remarkably promotes the antitumor activity[1].

in vivo

IDO/Tubulin-IN-2 (HT2) (30 mg/kg; IV; daily, for 21 days) significantly inhibits tumor growth^[1].
IDO/Tubulin-IN-2 (30 mg/kg; IV; 29 days) has effective antitumor immunity ability to promote the tumor therapeutic efficacy^[1].

Animal Model:	ICR mice (mouse liver cancer xenograft models, established by subcutaneous inoculation of H22 cells)^[1]
Dosage:	30 mg/kg
Administration:	Intravenously injected via a tail vein; daily, for 21 days
Result:	Significantly inhibited tumor growth.

Animal Model:	Male A549 tumor xenograft BALB/c nude mice (5 weeks, 18-22 g)^[1]
Dosage:	30 mg/kg
Administration:	IV, daily, for 29 days
Result:	Had effective antitumor immunity ability to promote the tumor therapeutic efficacy.

References

[1] Hua S, Chen F, Gou S. Microtubule inhibitors containing immunostimulatory agents promote cancer immunochemotherapy by inhibiting tubulin polymerization and tryptophan-2,3-dioxygenase. Eur J Med Chem. 2020;187:111949. DOI:10.1016/j.ejmech.2019.111949

Hazard Information

Uses

in vivo

References

Supplier